基于CIK细胞的免疫疗法治疗肾细胞癌研究进展  

Research progress in immunotherapy for renal cell carcinoma based on CIK cells

作　　者：李剑 侯恩存[2] LI Jian;HOU Encun(Guangxi University of Chinese Medicine,Guangxi,Nanning 530001,China;Ruikang Hospital Affiliated to Guangxi University of Chinese Medicine,Guangxi,Nanning 530000,China)

机构地区：[1]广西中医药大学,广西南宁530001 [2]广西中医药大学附属瑞康医院,广西南宁530000

出　　处：《中国医药科学》2023年第21期37-40,共4页China Medicine And Pharmacy

基　　金：广西重点研发计划(2021AB11025)。

摘　　要：细胞因子诱导的杀伤(CIK)细胞疗法是一种过继性细胞免疫疗法,由于其具有高增殖率和抗肿瘤特性,临床上各种实体瘤已被研究应用。肾细胞癌(RCC)是常见的泌尿生殖系统恶性肿瘤,由于手术、放化疗等传统治疗方式的总体缓解率有限,基于IL-2和IFN-α的免疫治疗效果不佳,故急需改善目前的治疗方式以增加患者的生存时间和提高其生活质量。因此,基于CIK细胞的免疫疗法应运而生。目前,CIK细胞在肾细胞癌中的应用已被众多研究评估,本文旨在总结基于CIK细胞的免疫疗法在肾细胞癌治疗中的安全性和疗效。Cytokine-induced killer(CIK)cell therapy is an adoptive cellular immunotherapy.Due to its high proliferation rate and anti-tumor properties,various solid tumors have been studied and applied clinically.Renal cell carcinoma(RCC)is a common malignant tumor of the genitourinary system.Due to the limited overall remission rate of traditional treatments such as surgery,radiotherapy and chemotherapy,etc.The effectiveness of immunotherapy based on IL-2 and IFN-αis not satisfactory,so there is an urgent need to improve the current treatment methods to increase the patient’s survival time and improve their quality of life.Therefore,immunotherapy based on CIK cells has emerged.At present,the application of CIK cells in renal cell carcinoma has been evaluated by numerous studies.This review aims to summarize the safety and efficacy of CIK cell-based immunotherapy in the treatment of renal cell carcinoma.

关 键 词：细胞因子诱导的杀伤细胞 免疫疗法 肾细胞癌 进展 

分 类 号：R730.51[医药卫生—肿瘤]